In Silico Exploration of few TriazoloPyrimidine Derivatives as Virtual Inhibitors against SARS-CoV-2 : A Comprehensive Analysis Integrating Molecular Docking and ADME-Toxicity Evaluation
-
Published:2024-01-01
Issue:
Volume:
Page:87-101
-
ISSN:2394-4099
-
Container-title:International Journal of Scientific Research in Science, Engineering and Technology
-
language:en
-
Short-container-title:IJSRSET
Author:
Janaki Chauhan 1, Dr. Bhavesh Dodiya 1, Dr. Girin Baxi 2
Affiliation:
1. Department of Chemistry Shri Ramji Ravji (R R) Lalan College, Bhuj, Gujarat, India 2. Department of Chemistry, KSKV Kutch university Bhuj, Gujarat, India
Abstract
This ground-breaking research delves into the potential of novel triazolopyrimidine derivatives as inhibitors of SARS-CoV, employing a robust in-silico approach that integrates molecular docking studies, molecular dynamics simulations, and comprehensive ADMET parameter assessments. The overarching goal is to identify compounds that exhibit both robust binding affinity and favourable pharmacokinetic profiles, laying the foundation for potential antiviral drug development. The methodology begins with the meticulous selection of triazolo pyrimidine derivatives based on their structural characteristics. Molecular docking studies are then conducted, focusing on a specific binding site on the SARS-CoV target. Subsequent molecular dynamics simulations provide a dynamic perspective on the stability of the binding interactions over time. ADMET parameter assessments are employed to evaluate drug-likeness and safety, crucial factors in determining the compounds' viability as potential drug candidates. The findings of this research underscore promising interactions between the triazolo pyrimidine derivatives and the targeted viral site, suggesting their potential as inhibitors of SARS-CoV. Importantly, the ADMET assessments contribute valuable insights into the pharmacokinetic properties of the compounds, informing their overall safety and suitability for further development. Notably, molecular docking studies include a comparative analysis with the standard antiviral drug remdesivir, revealing that the triazolo pyrimidine derivatives exhibit energy scores surpassing those of remdesivir. This finding signifies a potential advantage in terms of binding affinity and effectiveness against SARS-CoV. The implications of this research are profound, extending beyond the identification of potential inhibitors for SARS-CoV to contributing essential knowledge for the development of therapeutics against coronaviruses in general. This study serves as a crucial stepping stone for subsequent experimental validation and optimization of the identified compounds, propelling future drug discovery endeavours in the fight against coronaviral infections.
Publisher
Technoscience Academy
Reference20 articles.
1. Pismataro MC, Felicetti T, Bertagnin C, Nizi MG, Bonomini A, Barreca ML, Cecchetti V, Jochmans D, De Jonghe S, Neyts J, Loregian A, Tabarrini O, Massari S. 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. Eur J Med Chem. 2021 Oct 5;221:113494. doi: 10.1016/j.ejmech.2021.113494. 2. Massari S, Bertagnin C, Pismataro MC, Donnadio A, Nannetti G, Felicetti T, Di Bona S, Nizi MG, Tensi L, Manfroni G, Loza MI, Sabatini S, Cecchetti V, Brea J, Goracci L, Loregian A, Tabarrini O. Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase. Eur J Med Chem. 2021 Jan 1;209:112944. doi: 10.1016/j.ejmech.2020.112944. 3. Musa A, Abulkhair HS, Aljuhani A, Rezki N, Abdelgawad MA, Shalaby K, El-Ghorab AH, Aouad MR. Phenylpyrazolone-1,2,3-triazole Hybrids as Potent Antiviral Agents with Promising SARS-CoV-2 Main Protease Inhibition Potential. Pharmaceuticals (Basel). 2023 Mar 20;16(3):463. doi: 10.3390/ph16030463. PMID: 36986562; PMCID: PMC10051656. 4. Alamshany ZM, Khattab RR, Hassan NA, El-Sayed AA, Tantawy MA, Mostafa A, Hassan AA. Synthesis and Molecular Docking Study of Novel Pyrimidine Derivatives against COVID-19. Molecules. 2023 Jan 11;28(2):739. doi: 10.3390/molecules28020739. PMID: 36677798; PMCID: PMC9863666. 5. Muhammad ZA, Farghaly TA, Althagafi I, Al-Hussain SA, Zaki MEA, Harras MF. Synthesis of antimicrobial azoloazines and molecular docking for inhibiting COVID-19. J Heterocycl Chem. 2021 Jun;58(6):1286-1301. doi: 10.1002/jhet.4257. Epub 2021 Mar 21. PMID: 34230687; PMCID: PMC8250121.
|
|